Management

This page includes content on healthcare management, including health system, hospital, department and clinic business management and administration. Areas of focus are on cardiology and radiology department business administration. Subcategories covered in this section include healthcare economics, reimbursement, leadership, mergers and acquisitions, policy and regulations, practice management, quality, staffing, and supply chain.

Movie film cinema theater popcorn

Radiologists rarely represented in movies, limiting patient awareness about the specialty

Based on an IMDb search, radiologists appear as key parts of the plot in about 19 titles, with only nine available on major streaming platforms. 

ai in healthcare industry watchers blog digest

Industry Watcher’s Digest

Public interest is piqued over AI-aided cancer detection. 

Thumbnail

The top 25 children's heart hospitals in the US

Patient outcomes, safety data and physician feedback were all used to rank the top children's hospitals for pediatric cardiology and heart surgery in the United States. Did your facility make the cut? 

ai in healthcare bessemer venture partners

3 things AI startups, investors must know to clear hurdles in healthcare technology markets

As 2024 winds down and the number of FDA-approved medical devices packing AI approaches 1,000—the agency had the tally at 950 as of August—the industry finds itself at a “critical inflection point.” 

Thumbnail

AMA, physician groups file amicus brief with Supreme Court in ‘ghost gun’ case

The groups are urging the Supreme Court to uphold a lower court ruling in Garland v. VanDerStok that permits the ATF to regulate firearms made from part kits. 

Thumbnail

CMS proposes rule to combat gray market health insurance scams

The agency has received an increasing number of complaints from patients enrolled in a low-value health plan without their knowledge. If finalized, a new rule would empower CMS to ban brokers from the ACA marketplace. 

money business cash flow dollar

AstraZeneca spends up to $1.9B for new heart disease drug

Early data suggest the drug, an oral lipoprotein (a) disruptor, could make a significant impact on patient care. AstraZeneca will pay $100 million upfront, with much more to follow if certain milestones are met. 

Monitoring acute heart patients at home linked to considerable cost savings

The new report could go on to help guide decisions made by CMS and hospital leadership teams for years to come.